ClinicalTrials.gg
RecruitingNCT06370832Updated Nov 9, 2026

Inspiratory Muscle Training in Lung Transplant Candidates

An interventional study of IMT and exercise training group in Inspiratory Muscle Training, sponsored by University Health Network, Toronto. Recruiting at 4 sites in Canada. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-11-09.

Sponsored by University Health Network, Toronto · Not applicable, Interventional, and Treatment

How we know

From the registry’s dates

  • Started Aug 2024; still recruiting 2 years 3 months later.
Updated Nov 9, 2026Primary completion movedStudy completion movedGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
90
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 398 studies in Pulmonary Disease, Chronic Obstructive with a site in Canada — 40 open to participants now, 49 under way, 9 of them phase 3. Pulmonary Disease, Chronic Obstructive · Canada.

Planned enrollment
207th of 340
90 · median 207
Started
2024
with 11 others
No phase
120 of 398
19 open now
Primary completion
2027-09
later than 27 of 48 live
Registered
367th of 398
by date

Among the 398 studies in Pulmonary Disease, Chronic Obstructive with a site in Canada, this one is the 207th largest by planned enrollment of the 340 interventional ones that give a count, is one of 12 that started in 2024, is one of 120 with no phase, reaches primary completion later than 27 of the 48 other live ones, and was the 367th registered.

Pulmonary Disease, Chronic Obstructive

5,529 studies on the registry are indexed under Pulmonary Disease, Chronic Obstructive; 858 are open to participants now.

Browse Pulmonary Disease, Chronic Obstructive studies →

Open to participants now

40 of the 398 studies in Pulmonary Disease, Chronic Obstructive with a site in Canada are open now. Recruiting first, the newest first:

34 more — sign in →

All 40 open studies →

A study can be open while its sites in Canada have not opened yet or have stopped. Only those recruiting at a site in Canada →

Who these studies take

Of the 560 Pulmonary Disease, Chronic Obstructive studies recruiting now, 307 (55%) set no upper age limit and 82 (15%) stop at 75 or younger; 30 take children under 18; 88 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 398 studies in Pulmonary Disease, Chronic Obstructive with a site in Canada, or all of them as a file.
02

Study summary

Recovery after lung transplantation (LTx) may be complicated by prolonged mechanical ventilation (MV) and protracted intensive care unit (ICU) stay leading to immobilization and impaired health-related quality of life (HRQoL). In the critical care setting, diaphragm atrophy and weakness have been associated with difficulty weaning from MV, increased risk for readmission to hospital or ICU, and increased mortality. Increasing respiratory muscle strength by inspiratory muscle training (IMT) as part of pre-rehabilitation mitigates respiratory muscle dysfunction peri-operatively and may reduce the risk of post-operative complications. However, IMT is not widely used prior to LTx and the benefits of pre-operative IMT on post-transplant outcomes in LTx candidates have not been studied. Objectives: (1) To evaluate the feasibility of a multicenter randomized clinical trial of IMT in LTx candidates in terms of recruitment rate, retention, program adherence, and outcome ascertainment; (2) To establish the change in pre-transplant dyspnea perception, diaphragm structure and function, health related quality of life (HRQoL) and post-transplant intensive care unit (ICU), hospital and post-transplant 3-month outcomes with IMT relative to usual care group; and (3) To characterize the effect of pre-transplant IMT on peri-transplant diaphragm myofibrillar cross-sectional area (CSA), oxidative capacity, inflammatory markers and post-transplant diaphragm muscle thickness and function (UHN TGH site).

Read the detailed description

Diaphragm atrophy at the time of initiating mechanical ventilation (MV) after solid organ transplantation and major surgery is associated with prolonged MV and higher hospital mortality. The incidence of diaphragm dysfunction after LTx is estimated to be up to 30%; post-transplant diaphragm dysfunction is associated with prolonged MV and hospitalization after LTx.

The American Thoracic Society/European Respiratory Society (2013) guidelines recommend further evaluation of inspiratory muscle training (IMT) combined with routine rehabilitation prior to major surgery. Pre-operative IMT in patients with even normal maximal inspiratory pressures (MIP) have been shown to decrease post-operative pulmonary complications and shorten hospitalization after cardio-thoracic surgery. However, pre-operative IMT is not commonly used for LTx candidates and its benefits are poorly researched. IMT may prove to be a simple pre-transplant intervention to prevent post-transplant morbidity and improve post-transplant functional status. The current focus is to investigate the impact of IMT on early post-lung transplant results while evaluating its effectiveness through a pilot multicenter randomized controlled trial.

Objectives: 1) To evaluate the feasibility of a multicenter randomized clinical trial of IMT in LTx candidates in terms of recruitment rate, retention, program adherence, and outcome ascertainment.

2) To establish the change in pre-transplant dyspnea perception, diaphragm structure and function, health related quality of life (HRQoL) and post-transplant intensive care unit (ICU), hospital and post-transplant 3-month outcomes with IMT relative to usual care group.

3) To characterize the effect of pre-transplant IMT on peri-transplant diaphragm myofibrillar cross-sectional area (CSA), oxidative capacity, inflammatory markers and post-transplant diaphragm muscle thickness and function (UHN TGH site).

Hypotheses: 1) It will be feasible to recruit LTx candidates into an IMT program RCT with a consent rate ≥ 30 %, enrolment rate of 2-3 patients per month at UHN and 1 patient per month at each other participating site, adequate outcome ascertainment (≥ 80%), and acceptable adherence (≥ 80% compliance with IMT sessions). 2) IMT will increase respiratory muscle endurance by 20% and improve exertional dyspnea and HRQoL in comparison to usual care over the pre-transplant period. IMT will be associated with greater hospital free days at 90 days. 3) pre-transplant IMT increases diaphragm myofibrillar CSA and post-LTx diaphragm thickness and maximal diaphragm thickening during inspiration in comparison to usual care. The improved mitochondrial respiration will occur concurrently with improvements in muscle fiber size, immune infiltration and oxidative stress.

The IMT and exercise training group (IMT group) will perform two daily IMT sessions of 30 breaths (\< 5 minutes/session) during the pre-LTx period. IMT will start at 30% of MIP with a 5-10% weekly increase in training intensity guided by weekly MIP as tolerated (median weekly Borg dyspnea score \< 7 during IMT until reaching 70% of MIP) and continued until LTx. In conjunction with their IMT program, IMT group participants will undergo exercise training at least three times per week as part of their usual care. The control group (exercise training group) will perform exercise training as part of their usual care three times per week for the duration of the waitlist period. The exercise regimen for both groups consists of aerobic, resistance, and flexibility training supervised by a physiotherapist approximately three times a week. The training includes a combination of in-person visits and home-based sessions. Both groups will also receive a respiratory endurance device to evaluate respiratory endurance throughout the trial.

IMT can improve respiratory muscle strength and endurance, potentially helping those who are candidates for LTx. In addition, studying patients undergoing LTx affords unique opportunities to investigate the mechanistic effects of IMT on diaphragm structure and function.

03

Conditions studied

  • Inspiratory Muscle Training

Keywords

  • Lung transplant candidates
  • Exercise training
  • Prehabilitation
  • Chronic Obstructive Pulmonary Disease
  • Interstitial Lung Disease
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Adult participants (≥ 18 years of age)
  • Lung Transplant Candidates
  • Participating in outpatient pulmonary rehabilitation (standard of care)
  • Diagnosis of Interstitial Lung Disease or

Exclusion criteria

Exclusion Criteria:

  • Respiratory exacerbation within the last 1 month
  • Neurologic or musculoskeletal conditions that may interfere with IMT or functional assessments (i.e. history of stroke, severe arthritis of hands)
  • Insufficient English fluency to provide or to follow study protocols
  • Any evidence of pneumothorax on recent imaging (\< 6 months)
  • Present ruptures of eardrums or infections leading to fluid behind ear drum
  • Marked left or right ventricular end-diastolic volume and pressure overload on right heart catheterization or echocardiogram
  • Severe osteoporosis with history of rib fractures
  • Cardiac pacemaker or other electronic or magnetic body implant
  • Individuals listed as rapidly deteriorating or inpatient at the time of eligibility assessment
  • Individuals awaiting a re-transplant
  • Inability of the patient to connect to the internet
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

COPD

Chronic obstructive pulmonary disease: long-term lung disease that makes it hard to breathe out, including emphysema and chronic bronchitis.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Single (Outcomes assessor)
Enrollment
90 participants (estimated)

Study arms

  • Experimental
    IMT and exercise training group

    Participants in the IMT and exercise training group will perform twice daily 30-breath IMT sessions and exercise training sessions three times per week as part of their usual care during the pre-lung transplant phase. The exercise training is comprised of aerobic, resistance and flexibility training.

    Other: IMT and exercise training group

  • No intervention
    Usual care group

    Participants in the usual care group will take part in the standard of care rehabilitation program provided during the waitlist phase prior to the transplant. Exercise training is performed at least three times per week for the duration of the waitlist period. The exercise training includes a combination of supervised in-person visits and home-based training that incorporates aerobic, resistance and flexibility training.

Interventions

  • OtherIMT and exercise training group

    Participants will perform supervised exercise training per usual care and will be provided with a personalized prescription for an IMT program during the pre-transplant phase. Participants will perform two daily IMT sessions of 30 breaths (\< 5 minutes/session) 5 days per week in their home environment or in-person visits. IMT intensity will be progressed weekly by 5-10% of the baseline maximal inspiratory pressure if the Borg Dyspnea score is \< 7.

06

What researchers measure

Primary outcomes

  1. Study Recruitment According to Research Team Records

    Recruitment-success percentage in the study will be assessed based on research team study records.

    Time frame: Over study recruitment period (approximately 2 years)

  2. Participant Retention in the Study According to Research Team Records

    Participant retention will be assessed by measuring participant follow-up throughout the study period, according to research team records. A retention rate of 80% or greater (in each group) has been established as the criteria to determine study feasibility.

    Time frame: Over the study data collection period (from enrolment until 3 months post-transplant)

  3. Self-Reported Adherence to Inspiratory Muscle Training According to Participant IMT Diary

    Adherence to inspiratory muscle training will be assessed via the IMT training diary completed by participants. Successful adherence will be defined as completion of ≥ 80% training sessions.

    Time frame: Over intervention period (from randomization until time of transplantation, up to maximum of 24 months)

  4. Adverse Events and IMT Training Side Effects Reported by Participants

    Adverse events and training side-effects (e.g., muscle soreness) with inspiratory muscle training will be monitored through participant training diaries during the study intervention period. The research coordinator will review these diaries with participants on a weekly basis. Additionally, participants will be strongly encouraged to promptly inform the study team if they experience any challenges with IMT.

    Time frame: Over intervention period (from randomization until time of transplantation, up to maximum of 24 months)

  5. Inspiratory Muscle Training Satisfaction Questionnaire (IMT Group Only)

    Participant satisfaction and motivation with the IMT intervention will be determined using a satisfaction questionnaire.

    Time frame: At 3 months post-transplant follow-up

Secondary outcomes

  1. Respiratory Muscle Endurance Test

    Respiratory muscle endurance (measured in seconds) will be assessed at 30-50% of Maximum Inspiratory Pressure (MIP) using a manual threshold loading device (Powerbreathe Classic light resistance trainer)

    Time frame: Change from baseline at 4 weeks, 8 weeks, 12 weeks, every 3 months until lung transplant (up to 24 months total), and 3 months post-transplant

  2. Dyspnea Severity Assessed by Medical Research Council Dyspnea Scale

    The Medical Research Council Dyspnea Scale will be used to assess the effect of breathlessness on daily activities. The scale comprises five statements that describe the range of respiratory dyspnea from none (Grade 1) to severe with difficulties performing self-care (Grade 5).

    Time frame: Change from baseline at 4 weeks, 8 weeks, 12 weeks, every 3 months until lung transplant (up to 24 months total), and 3 months post-transplant

  3. Qualitative Measures of Dyspnea Assessed by Qualitative Dyspnea Scale

    The 18-point Qualitative Dyspnea Scale will be ascertained at each follow-up time point. Participants will be presented with a list of 18 qualitative descriptors of dyspnea experience and will be asked to rank their top three.

    Time frame: Change from baseline at 4 weeks, 8 weeks, 12 weeks, every 3 months until lung transplant (up to 24 months total), and 3 months post-transplant

  4. Mood Assessed by Depression, Anxiety, and Stress Scale

    The Depression, Anxiety and Stress Scale (DASS-21) questionnaire has 21 items to assess mood (anxiety, depression, and stress). Each statement for the three domains is given a score of 0 (not applicable) to 3 (applicable most of the time) with scores categorized as follows: Normal, Mild, Moderate, Severe, and Extremely Severe.

    Time frame: Change from baseline at 4 weeks, 8 weeks, 12 weeks, every 3 months until lung transplant (up to 24 months total), and 3 months post-transplant

  5. Health-Related Quality of Life Assessed by St. George's Respiratory Questionnaire

    Health-related Quality of Life (HRQL) will be assessed through the St. George's Respiratory Questionnaire (SGRQ) and consists of three domains (symptoms, activity and impacts) and total score. The SGRQ has a range of scores from 0 to 100 with higher scores signifying worse HRQL.

    Time frame: Change from baseline at 4 weeks, 8 weeks, 12 weeks, every 3 months until lung transplant (up to 24 months total), and 3 months post-transplant

  6. Respiratory Muscle Strength Assessed by Maximal Inspiratory Pressure

    Respiratory muscle strength will be quantified as Maximal Inspiratory Pressure (MIP), evaluated using a respiratory muscle trainer (PowerBreathe KH2).

    Time frame: Change from baseline at 4 weeks, 8 weeks, 12 weeks, every 3 months until lung transplant (up to 24 months total), time of liberation from mechanical ventilation, and 3 months post-transplant

  7. Physical Activity and Exercise Behaviors Assessed by International Physical Activity Questionnaire

    The International Physical Activity Questionnaire - Short Form (IPAQ-SF) will be used to measure physical activity levels in study participants. The questionnaire consists of seven questions to capture average daily time spent sitting, walking, and engaging in moderate and vigorous physical activity over the last seven days. The IPAQ-SF provides an overall physical activity level of participants based on their Metabolic Equivalent Task minutes per week.

    Time frame: Change from baseline at 4 weeks, 8 weeks, 12 weeks, every 3 months until lung transplant (up to 24 months total), and 3 months post-transplant

  8. Pulmonary Function Testing (Spirometry)

    Clinical charts will be reviewed to obtain results from spirometry assessments including Forced Vital Capacity (FVC), and Forced Expiratory Volume in the first second (FEV1).

    Time frame: Baseline, 4 weeks, 8 weeks, 12 weeks, every 3 months until lung transplant (up to 24 months total), and 3 months post-transplant

  9. Aerobic Endurance Assessed by the Six-Minute Walk Test

    Clinical rehabilitation charts will be reviewed to document aerobic endurance as assessed by distance walked during the Six-Minute Walk Test.

    Time frame: Baseline, 4 weeks, 8 weeks, 12 weeks, every 3 months until lung transplant (up to 24 months total), and 3 months post-transplant

  10. Physical Function Assessed by the Short Physical Performance Battery

    Clinical rehabilitation charts will be reviewed to document physical function as assessed by the Short-Physical Performance Battery, which evaluates balance, gait speed, and ability to rise from a chair 5 times.

    Time frame: Baseline, 4 weeks, 8 weeks, 12 weeks, every 3 months until lung transplant (up to 24 months total), and 3 months post-transplant

  11. Pre-Transplant Hospitalizations

    Clinical charts will be reviewed to document any hospitalizations and ICU admissions before the time of transplantation.

    Time frame: From baseline up until the time of admission for the index transplant hospitalization (up to 24 months total)

  12. Peri-Transplant Mechanical Ventilation Bridging

    Clinical charts will be reviewed to determine whether mechanical ventilation or extracorporeal membrane oxygenation (ECMO) were required as a bridge to transplantation.

    Time frame: Peri-operative period, from time of index transplant hospital admission to time of transplant surgery (up to 24 months total)

  13. Post-Transplant Duration of Mechanical Ventilation (Days)

    Clinical charts will be reviewed to determine the duration of mechanical ventilation required following transplantation surgery, measured in days.

    Time frame: From time of transplant surgery to the time of liberation from mechanical ventilation (up to 3 months total)

  14. WIND Weaning Classification

    The WIND weaning classification (short, difficult, or prolonged) will be ascertained by ICU staff at the time of liberation from mechanical ventilation based on the number of spontaneous breathing trials and weaning difficulty.

    Time frame: At the time of liberation from mechanical ventilation following transplant surgery (up to 3 months total).

  15. Post-Transplant Hospital Length of Stay (Days)

    Clinical charts will be reviewed to determine the length of stay in hospital following transplant surgery, measured in days.

    Time frame: From time of transplant surgery to the time of discharge from hospital (up to 3 months total).

  16. Post-Transplant Discharge Disposition

    Clinical charts will be reviewed to determine participants' discharge disposition from the index transplant hospitalization (e.g., home, inpatient rehabilitation, long-term care).

    Time frame: Time of discharge from index transplant hospitalization (up to 3 months total).

  17. Primary Graft Dysfunction

    Clinical charts will be reviewed to determine the presence and severity of primary graft dysfunction following transplant surgery.

    Time frame: Up to 72 hours post-transplant

  18. Post-Transplant Mortality

    Clinical charts will be reviewed to document post-transplant mortality and etiology.

    Time frame: Up to 90 days (3 months) post-transplant

  19. Days Alive and at Home at 90 Days (DAAH90)

    Clinical charts will be reviewed to determine the number of days participants are alive and at home at 90 days post-transplant.

    Time frame: Up to 90 days (3 months) post-transplant

Other outcomes

  1. Diaphragm Thickness and Thickening Fraction Assessed by Ultrasound

    The right hemi-diaphragm thickness and thickening fraction will be measured using a 13 Megahertz ultrasound transducer. Bright-mode (B-mode) ultrasound will be used to visualize the diaphragm and motion-mode (M-mode) will be utilized to assess the amplitude of the cranio-caudal diaphragmatic excursion during quiet and deep breathing. Diaphragm thickness will be measured in M-mode with a 5-13 MHz linear transducer over the apposition zone, near the costophrenic angle, from the most superficial hyperechoic line (pleural line) to the deepest hyperechoic line (peritoneal line).

    Time frame: Change from baseline to all on-site visits at 4 weeks, 8 weeks, 12 weeks, every 3 months until lung transplant (up to 24 months total), time of liberation from MV, and 3 months post-transplant

  2. Histopathology Analyses of Diaphragm Biopsies (Optional)

    Participants will have the option of consenting to diaphragm biopsies collected during the transplant surgery. Biopsies (50 mg) will be procured from the anterolateral region of the right costal hemi-diaphragm midway between the origin and insertion. A portion of the tissue sample (20mg) will be fixed in formalin for histopathology analyses including assessing fibre type distribution, fibre type-specific cross-sectional area, immune infiltration, oxidative capacity, and fibrosis using light microscopy.

    Time frame: At the time of lung transplantation, up to maximum of 24 months after randomization

  3. Biochemical Analyses of Diaphragm Biopsies (Optional)

    A second tissue portion (20mg) will be flash frozen in liquid nitrogen to assess mitochondrial content (via western blotting) and signaling cascades to examine atrophic signaling cascades using polymerase chain reactions.

    Time frame: At the time of lung transplantation, up to maximum of 24 months after randomization

  4. Mitochondrial Respirometry Analyses of Diaphragm Biopsies (Optional)

    The final tissue portion (10 mg) will be used for live assessments of mitochondrial function using the Oroboros O2K High Resolution Respiratory system on the day of transplantation, as quickly after biopsy collection as possible.

    Time frame: At the time of lung transplantation, up to maximum of 24 months after randomization

07

Study locations

4 of 4 sites recruiting
08

References and documents

Publications

  • Weill D, Benden C, Corris PA, Dark JH, Davis RD, Keshavjee S, Lederer DJ, Mulligan MJ, Patterson GA, Singer LG, Snell GI, Verleden GM, Zamora MR, Glanville AR. A consensus document for the selection of lung transplant candidates: 2014--an update from the Pulmonary Transplantation Council of the International Society for Heart and Lung Transplantation. J Heart Lung Transplant. 2015 Jan;34(1):1-15. doi: 10.1016/j.healun.2014.06.014. Epub 2014 Jun 26. PubMed 25085497 ↗
  • Hook JL, Lederer DJ. Selecting lung transplant candidates: where do current guidelines fall short? Expert Rev Respir Med. 2012 Feb;6(1):51-61. doi: 10.1586/ers.11.83. PubMed 22283579 ↗
  • Fuehner T, Kuehn C, Welte T, Gottlieb J. ICU Care Before and After Lung Transplantation. Chest. 2016 Aug;150(2):442-50. doi: 10.1016/j.chest.2016.02.656. Epub 2016 Mar 4. PubMed 26953218 ↗
  • Christie JD, Kotloff RM, Ahya VN, Tino G, Pochettino A, Gaughan C, DeMissie E, Kimmel SE. The effect of primary graft dysfunction on survival after lung transplantation. Am J Respir Crit Care Med. 2005 Jun 1;171(11):1312-6. doi: 10.1164/rccm.200409-1243OC. Epub 2005 Mar 11. PubMed 15764726 ↗
  • Adler D, Dupuis-Lozeron E, Richard JC, Janssens JP, Brochard L. Does inspiratory muscle dysfunction predict readmission after intensive care unit discharge? Am J Respir Crit Care Med. 2014 Aug 1;190(3):347-50. doi: 10.1164/rccm.201404-0655LE. No abstract available. PubMed 25084264 ↗
  • Sklar MC, Dres M, Fan E, Rubenfeld GD, Scales DC, Herridge MS, Rittayamai N, Harhay MO, Reid WD, Tomlinson G, Rozenberg D, McClelland W, Riegler S, Slutsky AS, Brochard L, Ferguson ND, Goligher EC. Association of Low Baseline Diaphragm Muscle Mass With Prolonged Mechanical Ventilation and Mortality Among Critically Ill Adults. JAMA Netw Open. 2020 Feb 5;3(2):e1921520. doi: 10.1001/jamanetworkopen.2019.21520. PubMed 32074293 ↗

Individual participant data

Plan to share: No

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it movedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Aug 2024 (actual). Primary completion is estimated for Sep 2027, 37 months after the start.

Of 1,099 non-industry interventional studies with no phase under Pulmonary Disease, Chronic Obstructive, half reached primary completion within 22 months of starting (the median), counting those still running; a quarter within 10 and three quarters within 41. This study's planned 37 months is above that.

Counting every sponsor, half of 1,187 studies reached it within 22 months; a quarter within 10 and three quarters within 39.

Since we started tracking on Sep 25, 2026, the dates moved once, on Nov 9, 2026: primary completion Sep 2026 → Sep 2027 and completion Sep 2027 → Mar 2028.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
Mar 4, 2024
First posted
Apr 17, 2024
StartActual
Aug 6, 2024
Primary completionEst.
Sep 30, 2027was Sep 2026
CompletionEst.
Mar 2028was Sep 2027
Last update
Nov 9, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Primary completion
Sep 30, 2026→Sep 30, 2027
Nov 9, 2026
Study completion
Sep 30, 2027→Mar 2028
Nov 9, 2026
Show all 1 update
  1. Nov 9, 2026
    Primary completion Sep 30, 2026→Sep 30, 2027
    Study completion Sep 30, 2027→Mar 2028
    + 2 other changes: verification date and site details

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT06370832
Collaborators
Canadian National Transplant Research Program, Canadian Institutes of Health Research (CIHR), Ozmosis Research Inc., Centre hospitalier de l'Université de Montréal (CHUM), Vancouver General Hospital
Responsible party
Sponsor
First posted
Apr 17, 2024
Start date
Aug 6, 2024
Primary completion
Sep 30, 2027 (estimated)
Completion
Mar 2028 (estimated)
Last update
Nov 9, 2026

Study contacts

Dmitry Rozenberg, MD, PhD
Contact
Dmitry.Rozenberg@uhn.ca
416-340-4800 ext. 7358
Dmitry Rozenberg, MD, PhD
principal investigator · University Health Network/University of Toronto

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion